Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natal...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4492934?pdf=render |
id |
doaj-2b20caecd36c47f4a6ab8bcb3152e1c0 |
---|---|
record_format |
Article |
spelling |
doaj-2b20caecd36c47f4a6ab8bcb3152e1c02020-11-25T02:28:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013180310.1371/journal.pone.0131803Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.Flavia MattioliChiara StampatoriFabio BellomiCristina ScarpazzaRuggero CapraPrevious studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natalizumab on cognitive impairment in a cohort of 24 consecutive patients with relapsing remitting MS treated for 3 years. The neuropsychological tests, as well as relapse number and EDSS, were assessed at baseline and yearly for three years. The impact on cortical atrophy was also considered in a subgroup of them, and are thus to be considered as preliminary. Results showed a significant reduction in the number of impaired neuropsychological tests after three years, a significant decrease in annualized relapse rate at each time points compared to baseline and a stable EDSS. In the neuropsychological assessment, a significant improvement in memory, attention and executive function test scores was detected. Preliminary MRI data show that, while GM volume did not change at 3 years, a significantly greater parahippocampal and prefrontal gray matter density was noticed, the former correlating with neuropsychological improvement in a memory test. This study showed that therapy with Natalizumab is helpful in improving cognitive performance, and is likely to have a protective role on grey matter, over a three years follow-up.http://europepmc.org/articles/PMC4492934?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Flavia Mattioli Chiara Stampatori Fabio Bellomi Cristina Scarpazza Ruggero Capra |
spellingShingle |
Flavia Mattioli Chiara Stampatori Fabio Bellomi Cristina Scarpazza Ruggero Capra Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. PLoS ONE |
author_facet |
Flavia Mattioli Chiara Stampatori Fabio Bellomi Cristina Scarpazza Ruggero Capra |
author_sort |
Flavia Mattioli |
title |
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. |
title_short |
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. |
title_full |
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. |
title_fullStr |
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. |
title_full_unstemmed |
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. |
title_sort |
natalizumab significantly improves cognitive impairment over three years in ms: pattern of disability progression and preliminary mri findings. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natalizumab on cognitive impairment in a cohort of 24 consecutive patients with relapsing remitting MS treated for 3 years. The neuropsychological tests, as well as relapse number and EDSS, were assessed at baseline and yearly for three years. The impact on cortical atrophy was also considered in a subgroup of them, and are thus to be considered as preliminary. Results showed a significant reduction in the number of impaired neuropsychological tests after three years, a significant decrease in annualized relapse rate at each time points compared to baseline and a stable EDSS. In the neuropsychological assessment, a significant improvement in memory, attention and executive function test scores was detected. Preliminary MRI data show that, while GM volume did not change at 3 years, a significantly greater parahippocampal and prefrontal gray matter density was noticed, the former correlating with neuropsychological improvement in a memory test. This study showed that therapy with Natalizumab is helpful in improving cognitive performance, and is likely to have a protective role on grey matter, over a three years follow-up. |
url |
http://europepmc.org/articles/PMC4492934?pdf=render |
work_keys_str_mv |
AT flaviamattioli natalizumabsignificantlyimprovescognitiveimpairmentoverthreeyearsinmspatternofdisabilityprogressionandpreliminarymrifindings AT chiarastampatori natalizumabsignificantlyimprovescognitiveimpairmentoverthreeyearsinmspatternofdisabilityprogressionandpreliminarymrifindings AT fabiobellomi natalizumabsignificantlyimprovescognitiveimpairmentoverthreeyearsinmspatternofdisabilityprogressionandpreliminarymrifindings AT cristinascarpazza natalizumabsignificantlyimprovescognitiveimpairmentoverthreeyearsinmspatternofdisabilityprogressionandpreliminarymrifindings AT ruggerocapra natalizumabsignificantlyimprovescognitiveimpairmentoverthreeyearsinmspatternofdisabilityprogressionandpreliminarymrifindings |
_version_ |
1724835305308028928 |